ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 503,27
-2,66%
Dow Jones
38 589,16
-0,15%
DAX
18 002,02
-1,43%
Brent Oil
82,275
0,00%
Bitcoin
66 142,85
0,21%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. BioCryst Pharmaceuticals Inc (BCRX)

  7. BioCryst Pharmaceuticals Inc (BCRX) Actualités

BCRX

BioCryst Pharmaceuticals (BCRX)

BioCryst Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:BCRX
DateHeureSourceTitreSymboleSociété
14/06/202422h33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
14/06/202422h08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
13/06/202422h23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BCRXBioCryst Pharmaceuticals Inc
04/06/202413h00GlobeNewswire Inc.BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BCRXBioCryst Pharmaceuticals Inc
02/06/202410h00GlobeNewswire Inc.BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) TreatmentNASDAQ:BCRXBioCryst Pharmaceuticals Inc
14/05/202413h00GlobeNewswire Inc.BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical ImmunologyNASDAQ:BCRXBioCryst Pharmaceuticals Inc
13/05/202413h00GlobeNewswire Inc.ORLADEYO® (berotralstat) Approved in MexicoNASDAQ:BCRXBioCryst Pharmaceuticals Inc
09/05/202413h00GlobeNewswire Inc.BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat)NASDAQ:BCRXBioCryst Pharmaceuticals Inc
07/05/202422h02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BCRXBioCryst Pharmaceuticals Inc
07/05/202413h00GlobeNewswire Inc.BioCryst to Present at Upcoming Investor ConferencesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
06/05/202413h00GlobeNewswire Inc.BioCryst Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:BCRXBioCryst Pharmaceuticals Inc
22/04/202413h00GlobeNewswire Inc.BioCryst to Report First Quarter 2024 Financial Results on May 6NASDAQ:BCRXBioCryst Pharmaceuticals Inc
17/04/202410h30GlobeNewswire Inc.BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory AgencyNASDAQ:BCRXBioCryst Pharmaceuticals Inc
27/02/202423h05Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:BCRXBioCryst Pharmaceuticals Inc
26/02/202413h00GlobeNewswire Inc.BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key MilestonesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
26/02/202411h57IH Market NewsU.S. Index Futures Dip Amid Inflation Data Anticipation, Oil and Iron Ore Prices RetreatNASDAQ:BCRXBioCryst Pharmaceuticals Inc
23/02/202413h00GlobeNewswire Inc.BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) TreatmentNASDAQ:BCRXBioCryst Pharmaceuticals Inc
19/02/202413h54GlobeNewswire Inc.BioCryst Launches ORLADEYO® (berotralstat) in ItalyNASDAQ:BCRXBioCryst Pharmaceuticals Inc
14/02/202422h21Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:BCRXBioCryst Pharmaceuticals Inc
14/02/202415h02Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:BCRXBioCryst Pharmaceuticals Inc
12/02/202413h00GlobeNewswire Inc.BioCryst to Report Fourth Quarter 2023 Financial Results on February 26NASDAQ:BCRXBioCryst Pharmaceuticals Inc
05/02/202413h00GlobeNewswire Inc.BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual MeetingNASDAQ:BCRXBioCryst Pharmaceuticals Inc
05/01/202422h01GlobeNewswire Inc.BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to ProfitabilityNASDAQ:BCRXBioCryst Pharmaceuticals Inc
03/01/202413h00GlobeNewswire Inc.BioCryst to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:BCRXBioCryst Pharmaceuticals Inc
19/12/202313h00GlobeNewswire Inc.BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO® (berotralstat)NASDAQ:BCRXBioCryst Pharmaceuticals Inc
29/11/202313h00GlobeNewswire Inc.BioCryst Announces Approval of ORLADEYO® (berotralstat) by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in ArgentinaNASDAQ:BCRXBioCryst Pharmaceuticals Inc
21/11/202313h00GlobeNewswire Inc.BioCryst Launches ORLADEYO® (berotralstat) in SpainNASDAQ:BCRXBioCryst Pharmaceuticals Inc
10/11/202313h00GlobeNewswire Inc.BioCryst Presents New Real-world Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-inhibitor Following Long-term Treatment with ORLADEYO® (berotralstat)NASDAQ:BCRXBioCryst Pharmaceuticals Inc
08/11/202322h29Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BCRXBioCryst Pharmaceuticals Inc
03/11/202317h03GlobeNewswire Inc.BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 MonthsNASDAQ:BCRXBioCryst Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:BCRX

Dernières Valeurs Consultées

NASDAQ
MSFT
Microsoft
NASDAQ
AMZN
Amazon.com
SPI
SP500
S&P 500
EU
BN
Danone
NYSE
NKE
Nike
EU
ACA
Credit Agricole
EU
RI
Pernod Ricard
EU
SGO
Cie de SaintGobain
COIN
BTCUSD
Bitcoin
EU
MC
Lvmh Moet Hennessy Louis...
EU
PX4
SBF 120
NYSE
MCD
McDonalds
EU
BNP
BNP Paribas
EU
DG
Vinci
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés